Registration Strip Icon for monitor Customisable watchlists with full streaming quotes from leading exchanges, such as LSE, NASDAQ, NYSE, AMEX, Bovespa, BIT and more.

Acurx Pharmaceuticals (ACXP)

Acurx Pharmaceuticals Inc
Date:
Sort by:
 Showing the most relevant articles for your search:NASDAQ:ACXP
DateTimeSourceHeadlineSymbolCompany
09/12/202413:00PR Newswire (US)Acurx Updates Phase 3 Readiness for Ibezapolstat in C. difficile Infection Based on Recent FDA and EMA CommunicationsNASDAQ:ACXPAcurx Pharmaceuticals Inc
20/11/202412:01PR Newswire (US)Acurx Board of Directors Approves Bitcoin as Treasury Reserve AssetNASDAQ:ACXPAcurx Pharmaceuticals Inc
20/11/202412:01PR Newswire (US)Acurx Board of Directors Approves Bitcoin as Treasury Reserve AssetNASDAQ:ACXPAcurx Pharmaceuticals Inc
13/11/202412:06Edgar (US Regulatory)Form 8-K - Current reportNASDAQ:ACXPAcurx Pharmaceuticals Inc
13/11/202412:00PR Newswire (US)Acurx Pharmaceuticals, Inc. Reports Third Quarter 2024 Results and Provides Business UpdateNASDAQ:ACXPAcurx Pharmaceuticals Inc
21/10/202411:00PR Newswire (US)Acurx Announces New Bile Acid and Microbiome Analyses from Ph2b Trial of Ibezapolstat in CDI Patients Presented at IDWeek Scientific ConferenceNASDAQ:ACXPAcurx Pharmaceuticals Inc
17/10/202412:00PR Newswire (US)Acurx Pharmaceuticals Announces Participation at The Spartan Capital Investor Conference to Showcase Growth Companies and Foster High-Level Investor EngagementNASDAQ:ACXPAcurx Pharmaceuticals Inc
16/10/202412:00PR Newswire (US)Acurx Pharmaceuticals to Discuss Third Quarter 2024 Financial Results on November 13, 2024NASDAQ:ACXPAcurx Pharmaceuticals Inc
26/09/202411:00PR Newswire (US)Acurx Announces Additional Ibezapolstat Ph2b Results in CDI as well as Anthrax (B. anthracis) Susceptibility to ACX-375 AnaloguesNASDAQ:ACXPAcurx Pharmaceuticals Inc
24/09/202411:00PR Newswire (US)Acurx Announces Results of Its Pioneering Research with Ibezapolstat in Collaboration with Leiden University Medical Center at the Premier International C. difficile SymposiumNASDAQ:ACXPAcurx Pharmaceuticals Inc
26/08/202413:15GlobeNewswire Inc.New to The Street Announces its Five Corporate Interviews, Airing Episode 591 on the Fox Business Network, Tonight Monday, August 26, 2024, at 10:30 PM PTNASDAQ:ACXPAcurx Pharmaceuticals Inc
26/08/202411:00PR Newswire (US)ACURX PHARMACEUTICALS ANNOUNCES PARTICIPATION AT THE H.C. Wainwright 26th Annual Global Investment ConferenceNASDAQ:ACXPAcurx Pharmaceuticals Inc
19/08/202413:20GlobeNewswire Inc.New to The Street Announces Episode 590, Five Corporate Interviews, Airing on the Fox Business Network, Tonight Monday, August 19, 2024, at 10:30 PM PTNASDAQ:ACXPAcurx Pharmaceuticals Inc
09/08/202413:30GlobeNewswire Inc.New to The Street TV Announces Episode 583, Five Riveting Business Guest Interviews, Airs on Bloomberg TV as Sponsored Programming, Saturday, August 10, 2024, at 6:30 PM ETNASDAQ:ACXPAcurx Pharmaceuticals Inc
09/08/202411:13Edgar (US Regulatory)Form 8-K - Current reportNASDAQ:ACXPAcurx Pharmaceuticals Inc
09/08/202411:01PR Newswire (US)Acurx Pharmaceuticals, Inc. Reports Second Quarter 2024 Results and Provides Business UpdateNASDAQ:ACXPAcurx Pharmaceuticals Inc
17/07/202411:00PR Newswire (US)USPTO Grants Acurx Pharmaceuticals New Patent for Ibezapolstat to Treat CDI While Reducing Recurrence of Infection and Improving Health of the Gut MicrobiomeNASDAQ:ACXPAcurx Pharmaceuticals Inc
16/07/202411:00PR Newswire (US)Acurx Pharmaceuticals, Inc. to Discuss Second Quarter 2024 Financial Results on August 9, 2024 Conference Call and Provide Business UpdateNASDAQ:ACXPAcurx Pharmaceuticals Inc
15/07/202411:00PR Newswire (US)Acurx Pharmaceuticals Announces Presentation of Ibezapolstat Phase 2 Clinical Trial Results for CDI at Scientific ConferenceNASDAQ:ACXPAcurx Pharmaceuticals Inc
18/06/202420:14Edgar (US Regulatory)Form 4 - Statement of changes in beneficial ownership of securitiesNASDAQ:ACXPAcurx Pharmaceuticals Inc
18/06/202420:11Edgar (US Regulatory)Form 4 - Statement of changes in beneficial ownership of securitiesNASDAQ:ACXPAcurx Pharmaceuticals Inc
17/06/202420:14Edgar (US Regulatory)Form 8-K - Current reportNASDAQ:ACXPAcurx Pharmaceuticals Inc
06/06/202413:30GlobeNewswire Inc.New to The Street Announces Episode 576, Four Business Guest Interviews, Airs on Bloomberg TV as Sponsored Programming, Tonight, Thursday, June 6, 2024, at 9:30 PM PTNASDAQ:ACXPAcurx Pharmaceuticals Inc
15/05/202413:00PR Newswire (US)Acurx Announces Successful FDA End-of-Phase 2 Meeting and Phase 3 Readiness for Ibezapolstat in the Treatment of C. difficile InfectionNASDAQ:ACXPAcurx Pharmaceuticals Inc
15/05/202411:50IH Market NewsU.S. Index Futures Flat Ahead of April CPI Data Release, Oil Prices DropNASDAQ:ACXPAcurx Pharmaceuticals Inc
15/05/202411:13Edgar (US Regulatory)Form 8-K - Current reportNASDAQ:ACXPAcurx Pharmaceuticals Inc
15/05/202411:00PR Newswire (US)Acurx Pharmaceuticals, Inc. Reports First Quarter 2024 Results and Provides Business UpdateNASDAQ:ACXPAcurx Pharmaceuticals Inc
14/05/202420:05Edgar (US Regulatory)Form 10-Q - Quarterly report [Sections 13 or 15(d)]NASDAQ:ACXPAcurx Pharmaceuticals Inc
02/05/202411:00PR Newswire (US)Acurx Pharmaceuticals Announces Presentation of Ibezapolstat Phase 2 Clinical Trial Results at ESCMID Global 2024 Scientific ConferenceNASDAQ:ACXPAcurx Pharmaceuticals Inc
25/04/202414:12PR Newswire (US)Acurx Pharmaceuticals Announces Presentation of Ibezapolostat Phase 2 Clinical Trial Results at upcoming ESCMID 2024 Scientific ConferenceNASDAQ:ACXPAcurx Pharmaceuticals Inc
 Showing the most relevant articles for your search:NASDAQ:ACXP